Neuroectodermal Tumors clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
open to eligible people ages 1 year and up
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
San Francisco, California and other locations
Our lead scientists for Neuroectodermal Tumors research studies include Kieuhoa Vo.
Last updated: